Ifosfamide and vinorelbine as first-line chemotherapy for advanced non- small cell lung carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 6, 1996, Pages 584-588

  Vallejo, C ^a   Romero, A ^a   Perez, J ^a   Cuevas, M ^a   Lacava, J ^a   Sabatini, C ^a   Dominguez, M ^a   Rodriguez, R ^a   Barbieri, M ^a   Romero Acuna L ^a   Romero Acuna J ^a   Langhi, M ^a   Amato, S ^a   Salvadori, M ^a   Ortiz, E ^a   Machiavelli, M ^a   Leone, B ^a  

^a Grupo Oncologico Cooperativo del Sur   (Argentina)

Author keywords

Ifosfamide; Lung cancer; Vinorelbine

Indexed keywords

HEMOGLOBIN; IFOSFAMIDE; MESNA; NAVELBINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHLEBITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BRAIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EXPECTORANTS; FEMALE; HUMANS; IFOSFAMIDE; LEUKOPENIA; LUNG NEOPLASMS; MALE; MESNA; MIDDLE AGED; NEOPLASM STAGING; PERIPHERAL NERVES; PHLEBITIS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT FAILURE; VINBLASTINE;

EID: 0029827541     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199612000-00011     Document Type: Article

References (30)

1. Sculier JP, Klastersky J. Progress in chemotherapy of non- small cell lung cancer. Eur J Cancer Clin Oncol 1989;20:1329- 33.
2. Williams CJ, Woods R, Page J. Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine vs no chemotherapy. Semin Oncol 1988;15:58-61.
3. Rapp E, Pater J, Willan A, et al. A comparison of best supportive care to two regimens of combination chemotherapy in the management of advanced non-small cell lung cancer (NSCLC): a report of a Canadian multicenter trial. J Clin Oncol 1988;6: 633-41.
4. Ganz PA, Giflin RA, Haskell CM, et al. Supportive care vs supportive care plus chemotherapy in advanced metastatic lung cancer: response, survival and quality of life [Abstract]. Proc Am Soc Clin Oncol 1987;6:171.
5. Cormier Y, Bergerson D, LaForge J, et al. Benefit of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 1982;50:845-9.
6. Ginsberg R, Kris MG, Armstrong JG. Cancer of the lung. In: De Vita V Jr, Hellman S, Rosemberg S, eds. Cancer: principles and practice of oncology, Philadelphia: Lippincott, 1993:673- 758.
7. Costanzi JJ, Morgan LR, Hokanson J. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin Oncol 1982;9:61-5.
8. Jose RA, Cavalli F, Goldhirsch A, et al. New agents in non- small cell lung cancer. Cancer Treat Rev 1984;11:205-36.
9. Drings P. Ifosfamide in the treatment of bronchial carcinoma. In: Brade WP, Nagel GA, Seeber S, eds. Ifosfamide in tumor therapy. Basel, Switzerland: Karger, 1987:294-318.
10. Holoye PY, Glisson BS, Lee JS, et al. Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol 1990;13:148-55.
11. Loehrer PJ, Birch R, Kramer BS. et al. Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:919-20.
12. Goldin A: Ifosfamide in experimental tumor systems. Semin Oncol 1982;4:14-23.
13. Cros S, Wright M, Morimoto M, et al. Experimental antitumor activity of Navelbine. Semin Oncol 1989;16:15-20.
14. Langlois N, Gueritte F, Langlois Y, et al. Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloid. J Am Chem Soc 1976;22:7017-24.
15. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 1989;16:9-14.
16. Le Chevallier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
17. Goa KL, Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 1994;5:200-34.
18. Drinkard L, Hoffman P, Bitran J, et al. Ifosfamide (I) in combination with Navelbine (N) or taxol (T) and granulocyte-colony stimulating factors (G-CSF) support in advanced non- small cell lung cancer (NSCLC): 2 parallel phase I-II trials [Abstract], Proc Am Soc Clin Oncol 1994;13:354.
19. Marantz A, Lewis D, Litovska S. Phase II study of vinorelbine (VN) and ifosfamide (IPX) for non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol 1994;13:325.
20. Morere JM, Piperno-Neumann S, Brunet A, et al. Navelbine (NVB) and ifosfamide (IPX) for unresectable non-small cell lung cancer (NSCLC) [Abstract]. Proc Eur Soc Med Oncol 1994;5(8):153.
21. American Joint Committee on Cancer Staging and End-Results Reporting (AJC). Manual for staging of cancer. 3rd ed. Philadelphia: Lippincott, 1988:115-21.
22. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
23. Perry MC. Appendix - WHO toxicity guidelines. In: Perry MC, ed. The chemotherapy source book. Baltimore, MD: Williams & Wilkins, 1992:1132-44.
24. Thürlimann B, Bachman I. Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomized trial. Ann Oncol 1992;3:311-3.
25. Kaplan EC, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:437-81.
26. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2: 1281-8.
27. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's prime. J Clin Oncol 1985;3:1418-31.
28. Vallejo CT, Rabinovich MG, Perez JE, et al. High-dose Cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncológico Cooperative del Sur study. Am J Clin Oncol 1995;18(3):185-8.
29. Sorensen JB. Current position of vinorelbine in cancer chemotherapy [Editorial]. Ann Oncol 1995;6:105-7.
30. Gralla RJ, Kardinal CG, Clark RA, et al. Enhancing the safety, efficacy and dose intensity of vinorelbine (Navelbine) in combination chemotherapy regimens [Abstract]. Proc Am Soc Clin Oncol 1993;12:336.